Kelyniam Global Announces Record Sales of $3 million in 2022 Financial Statements.

CANTON, Conn: Kelyniam Global (OTC: KLYG), a maker of custom cranial implants, today announced results for its year ended December 31, 2022.

"2022 was the sixth year in a row that Kelyniam has meaningfully increased sales while successfully competing against much larger competitors," said Ross Bjella, Kelyniam's CEO. "Neurosurgeons rely on our ability to manufacture and ship PEEK custom cranial implants within 24 hours, a service level that none of our competitors can match. Hospital buyers appreciate the savings associated with our patented, fully integrated fixation system that eliminates the need for plates and requires fewer screws."

Financial highlights for the year ended December 31, 2022 and the same period in 2021 include:

Total revenue of $3,017,599 compared to $2,664,434, an increase of 13.2%

Operating income of $69,322 compared to $180,445

Net Loss of $97,560 compared to net income of $201,741

Operating income is not comparable to 2021 numbers because of PPP loan forgiveness. Net income in 2022 was affected by non-cash legacy stock award grants dating...